{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:45:26Z","timestamp":1762505126246,"version":"build-2065373602"},"reference-count":31,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2006,5,9]],"date-time":"2006-05-09T00:00:00Z","timestamp":1147132800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2006,6]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To evaluate the clinical efficacy and tolerability of tolterodine extended\u2010release (ER) in continent patients with overactive bladder (OAB) and nocturia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>\n                      A\n                      <jats:italic>post hoc<\/jats:italic>\n                      analysis was conducted of data from a 12\u2010week, double\u2010blind study of 850 patients randomized to tolterodine ER (4\u2003mg once daily) or placebo, taken within 4\u2003h of going to bed. Patients with a mean of \u2265\u200a8 voids\/24\u2003h were enrolled, including a mean of \u2265\u200a2.5 voids\/night. Patients completed 7\u2010day voiding diaries, and for each void an urgency rating was assessed using a 5\u2010point scale (1, none; 5, urgency incontinence); 24\u2010h voids were categorized by urgency rating: total (1\u20135), non\u2010OAB (1\u20132), OAB (3\u20134), and severe OAB (4\u20135) voids. All adverse events were recorded.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      The\n                      <jats:italic>post hoc<\/jats:italic>\n                      analysis included 513 patients (243 placebo; 270 tolterodine ER; 58% men) who were continent at baseline; 47% of 24\u2010h voids were classed as non\u2010OAB, and 12% as severe OAB. After 12\u2003weeks of treatment, tolterodine ER significantly reduced mean urgency rating and 24\u2010h OAB, severe OAB, and total voids vs placebo. Tolterodine ER did not affect normal, non\u2010OAB voids, and there were no significant adverse events related to voiding. Other than dry mouth (tolterodine ER, 9% vs placebo, 2%), all the adverse events were reported in &lt;3% of patients; &lt;2% of patients receiving tolterodine ER withdrew because of adverse events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>In continent patients with OAB, tolterodine ER significantly improved urgency rating and reduced 24\u2010h OAB, severe OAB, and total voids, suggesting that it is an effective and well\u2010tolerated treatment option for this subpopulation. More studies are needed to better understand the clinical efficacy of tolterodine ER in this under evaluated group of OAB patients without incontinence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2006.06146.x","type":"journal-article","created":{"date-parts":[[2006,5,9]],"date-time":"2006-05-09T09:20:39Z","timestamp":1147166439000},"page":"1262-1266","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Efficacy and tolerability of tolterodine extended\u2010release in continent patients with overactive bladder and nocturia"],"prefix":"10.1111","volume":"97","author":[{"given":"VICTOR W.","family":"NITTI","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ROGER","family":"DMOCHOWSKI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RODNEY A.","family":"APPELL","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JOSEPH T.","family":"WANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TAMARA","family":"BAVENDAM","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ZHONGHONG","family":"GUAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the 037 Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,5,9]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)02243-4"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)01784-3"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(00)01113-4"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(02)85137-2"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006250-200309000-00033"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200427130-00005"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)68810-6"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.2165\/00044011-200019020-00001"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)66095-8"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-2115(00)00561-3"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64684-8"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.4065\/78.6.687"},{"key":"e_1_2_8_14_2","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s00345-003-0321-8","article-title":"Controlled, double\u2010blind, multicentre clinical trial to investigate long\u2010term tolerability and efficacy of trospium chloride in patients with detrusor instability","volume":"20","author":"Halaska M","year":"2003","journal-title":"World J Urol"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(04)90174-9"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000140729.07840.16"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2004.04606.x"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2004.01.008"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000127742.73136.0c"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02228.x"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02228.x"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.10.061"},{"key":"e_1_2_8_23_2","unstructured":"European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products.Note for Guidance on the Clinical Investigation of Medicinal Products for the Treatment of Urinary Incontinence. Report no. CPMP\/EWP\/18\/01 London:December 2002"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80126-0"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(01)00986-4"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2003.04527.x"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2004.74008.x"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079902125000570"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(02)00177-X"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0302-2838(01)00009-4"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.10162"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)02505-0"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2006.06146.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2006.06146.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:10:20Z","timestamp":1761739820000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2006.06146.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,9]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["10.1111\/j.1464-410X.2006.06146.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2006.06146.x","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"type":"print","value":"1464-4096"},{"type":"electronic","value":"1464-410X"}],"subject":[],"published":{"date-parts":[[2006,5,9]]},"assertion":[{"value":"2006-05-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}